Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Psoriasis Treatment Market by Drug Class [TNF Alpha Inhibitors [Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Cimzia (cetolizumab)], Interleukin Inhibitors [Skyrizi (risankizumab), Siliq (brodalumab), Taltz (ixekizumab), Cosentyx (secukinumab), Stelara (ustekinumab), Tremfya (guselkumab), Ilumya (tildrakizumab), Bimzelx (bimekizumab)], PDE4 Inhibitors [Otezla (apremilast)], TYK2 Inhibitors [Sotyktu (deucravacitinib)], Others (Vitamin D Analogues, Topical Ointment, Corticosteroids, Anti-inflammatory)], Pipeline Analysis and Forecast 2024-2031


Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Psoriasis is a long-lasting autoimmune disease which is characterized by patches of abnormal skin. It is often diagnosed or at least suspected on the basis of its appearance and distribution. There is no cure for psoriasis, however, various treatments can help control the symptoms.

Topical treatments such as form of lotions, foams, creams, ointments, gels, and shampoos containing steroids, tar preparations, and calcium- modulating drugs are very useful because they are relatively safe, fairly effective, and can be applied directly to the affected skin.

Most oral medications act by targeting portions of the immune system. Phototherapy or light therapy involves exposing the skin to ultraviolet light on a regular basis and under medical supervision.

Biologic drugs are usually prescribed for moderate to severe psoriasis and psoriatic arthritis that has not responded to other treatments.

Treatments for more advanced psoriasis include narrow-band ultraviolet B (UVB) light, psoralen with ultraviolet A (UVA) light retinoids (isotretinoin [Accutane, Claravis], acitretin [Soriatane]), methotrexate (particularly for arthritis), cyclosporine (Neoral, Sandimmune), infliximab (Remicade), etanercept (Enbrel), adalimumab (Humira), apremilast (Otezla), and secukinumab (Cosentyx). Currently, calcineurin inhibitors such as tacrolimus (Prograf) and pimecrolimus (Elidel) are approved only for the treatment of atopic dermatitis.

Vitamin D analogues such as Calcipotriene (Dovonex) slow down the growth of skin cells.

The global psoriasis treatment market report provides market size ($Million 2021 to 2031), market share, trends and forecast (CAGR%, 2024 to 2031).

The global psoriasis treatment market segmentation is based on drug class [TNF alpha inhibitors [Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Cimzia (cetolizumab)], interleukin inhibitors [Skyrizi (risankizumab), Siliq (brodalumab), Taltz (ixekizumab), Cosentyx (secukinumab), Stelara (ustekinumab), Tremfya (guselkumab), Ilumya (tildrakizumab)], PDE4 Inhibitors [Otezla (apremilast)], TYK2 inhibitors [Sotyktu (deucravacitinib), others (vitamin D analogues, topical ointment, corticosteroids, anti-inflammatory)], pipeline analysis, and geography.

The global psoriasis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

The global psoriasis treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global psoriasis treatment market and profiled in this report include AbbVie, Inc., Amgen, Inc., Biogen, Inc. Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson and Johnson (Janssen Biotech, Inc.), LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Ortho Dermatologics, Sun Pharmaceutical Industries Ltd., and UCB (Union Chimique Belge).

DATA INCLUDED: Psoriasis Treatment Market Size, Psoriasis Treatment Market Share, Psoriasis Treatment Market Growth Rates, Psoriasis Treatment Market Trends, and Psoriasis Treatment Market Forecast to 2031

Market Data:

  • Base year for estimation: 2023
  • Actual estimates/Historical data: 2021-2031
  • Forecast period: 2024-2031
  • Market representation: Revenue in $million and CAGR % from 2024 to 2031
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us for offers on individual or multiple report purchases.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2021-2031)
    • Forecast Estimation ($million and CAGR%, 2024-2031)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2031)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Psoriasis Treatment Market

1. Drug Class
1.1. Tumor Necrosis Factor (TNF) Alpha Inhibitors
1.1.1. Humira (adalimumab)
1.1.2. Enbrel (etanercept)
1.1.3. Remicade (infliximab)
1.1.4. Cimzia (cetolizumab pegol)
1.2. Interleukin Inhibitors
1.2.1. Skyrizi (risankizumab)
1.2.2. Siliq (brodalumab)
1.2.3. Taltz (ixekizumab)
1.2.4. Cosentyx (secukinumab)
1.2.5. Stelara (ustekinumab)
1.2.6. Tremfya (guselkumab)
1.2.7. Ilumya (tildrakizumab)
1.3. PDE4 Inhibitors
1.3.1. Otezla (apremilast)
1.4. TYK2 Inhibitors
1.4.1. Sotyktu (deucravacitinib)
1.5. Others (Vitamin D Analogues, Topical Ointment, Corticosteroids, Anti-inflammatory)

2. Pipeline Analysis

3. Geography
3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Asia Pacific (Japan, China, India, Rest of APAC)
3.4. Latin America (Brazil, Mexico, Rest of LA)
3.5. Rest of the World

4. Company Profiles
4.1. AbbVie, Inc.
4.2. Amgen, Inc.
4.3. Biogen, Inc.
4.4. Bristol-Myers Squibb Company
4.5. Eli Lilly and Company
4.6. Johnson and Johnson (Janssen Biotech Inc.)
4.7. LEO Pharma A/S
4.8. Merck & Co., Inc.
4.9. Novartis AG
4.10. Ortho Dermatologics
4.11. Sun Pharmaceutical Industries Ltd.
4.12. UCB (Union Chimique Belge)

    Request ToC / Sample Report

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com